{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:11:02Z","timestamp":1793041862657,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Chemistry"],"DOI":"10.1186\/s13065-025-01470-w","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T16:06:39Z","timestamp":1745683599000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Post-marketing quality assessment of some brands of rosuvastatin tablets available in Jos, North-Central Nigeria"],"prefix":"10.1186","volume":"19","author":[{"given":"Ukpe","family":"Ajima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary Chioma","family":"Omeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnson Ogoda","family":"Onah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Owunebe","family":"Ehoche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"issue":"25 Suppl 2","key":"1470_CR1","first-page":"S1","volume":"129","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1-45.","journal-title":"Circulation"},{"issue":"10","key":"1470_CR2","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41569-021-00541-4","volume":"18","author":"A Pirillo","year":"2021","unstructured":"Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidaemias. Nat Rev Cardiol. 2021;18(10):689\u2013700. https:\/\/doi.org\/10.1038\/s41569-021-00541-4.","journal-title":"Nat Rev Cardiol"},{"key":"1470_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-89908-6.00002-9","volume-title":"Probiotic for dyslipidemia prevention and treatment","author":"JL de Brito Alves","year":"2022","unstructured":"de Brito Alves JL, Trindade da Costa PC. Probiotic for dyslipidemia prevention and treatment. London: Academic Press; 2022."},{"key":"1470_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713288","author":"J Dybiec","year":"2023","unstructured":"Dybiec J, Baran W, D\u0105bek B, Fularski P, M\u0142ynarska E, Radzioch E, et al. Advances in treatment of dyslipidemia. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241713288.","journal-title":"Int J Mol Sci"},{"key":"1470_CR5","doi-asserted-by":"publisher","first-page":"4782344","DOI":"10.1155\/2022\/4782344","volume":"2022","author":"S Mosca","year":"2022","unstructured":"Mosca S, Ara\u00fajo G, Costa V, Correia J, Bandeira A, Martins E, et al. Dyslipidemia diagnosis and treatment: risk stratification in children and adolescents. J Nutr Metab. 2022;2022:4782344.","journal-title":"J Nutr Metab"},{"issue":"9","key":"1470_CR6","doi-asserted-by":"publisher","first-page":"e940","DOI":"10.1016\/S2214-109X(18)30305-X","volume":"6","author":"FS Sarfo","year":"2018","unstructured":"Sarfo FS. Dyslipidaemia among African adults. Lancet Glob Heal. 2018;6(9):e940\u20131. https:\/\/doi.org\/10.1016\/S2214-109X(18)30305-X.","journal-title":"Lancet Glob Heal"},{"issue":"3","key":"1470_CR7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.gheart.2017.03.002","volume":"12","author":"A Murphy","year":"2017","unstructured":"Murphy A, Faria-Neto JR, Al-Rasadi K, Blom D, Catapano A, Cuevas A, et al. World heart federation cholesterol roadmap. Glob Heart. 2017;12(3):179-197.e5.","journal-title":"Glob Heart"},{"key":"1470_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-801238-3.03870-8","volume-title":"Lipid Disorders in the Elderly","author":"WS Aronow","year":"2014","unstructured":"Aronow WS. Lipid Disorders in the Elderly. Oxford: Academic Press; 2014."},{"key":"1470_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9091078","author":"R Fiorentino","year":"2021","unstructured":"Fiorentino R, Chiarelli F. Treatment of dyslipidaemia in children. Biomedicines. 2021. https:\/\/doi.org\/10.3390\/biomedicines9091078.","journal-title":"Biomedicines"},{"key":"1470_CR10","volume-title":"Statins","author":"L Tokg\u00f6zo\u011flu","year":"2024","unstructured":"Tokg\u00f6zo\u011flu L, Carl O, Saseen JJ. Statins. New Delhi: Elsevier; 2024."},{"issue":"3","key":"1470_CR11","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3390\/scipharm84030536","volume":"84","author":"AN Zaid","year":"2016","unstructured":"Zaid AN, Al Ramahi R, Cortesi R, Mousa A, Jaradat N, Ghazal N, et al. Investigation of the bioequivalence of Rosuvastatin 20 mg tablets after a single oral administration in Mediterranean Arabs using a validated LC-MS\/MS method. Sci Pharm. 2016;84(3):536\u201346.","journal-title":"Sci Pharm"},{"key":"1470_CR12","unstructured":"BP. British Pharmacopoeia. London: The Pharmaceutical Press, Her Majestys Stationary Office. 2024."},{"key":"1470_CR13","unstructured":"Radwany NY. In vitro and in vivo Post-marketing Surveillance of Rosuvastatin among Palestinian Patients. 2021."},{"issue":"7","key":"1470_CR14","doi-asserted-by":"publisher","first-page":"100956","DOI":"10.1016\/j.cpcardiol.2021.100956","volume":"47","author":"A Rahhal","year":"2022","unstructured":"Rahhal A, Khir F, Orabi B, Chbib S, Al-Khalaila O, Abdelghani MS, et al. A comparative study of high-intensity rosuvastatin versus atorvastatin therapy post-acute coronary syndrome using real-world data. Curr Probl Cardiol. 2022;47(7):100956.","journal-title":"Curr Probl Cardiol"},{"issue":"12","key":"1470_CR15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.4236\/ijcm.2019.1012052","volume":"10","author":"S Shaheen","year":"2019","unstructured":"Shaheen S, Elserafy ASH, Amin M, Hassan R, Issak ER. Brand versus generic rosuvastatin in egyptian patients with hyperlipidemia cost-minimization analysis. Int J Clin Med. 2019;10(12):631\u20138.","journal-title":"Int J Clin Med"},{"key":"1470_CR16","unstructured":"USP. The United State Pharmacopeia. Rockville (MD): The United States Pharmacopeial Convention. 2024."},{"issue":"6","key":"1470_CR17","first-page":"411","volume":"62","author":"B Uyar","year":"2007","unstructured":"Uyar B, Celebier M, Altinoz S. Spectrophotometric determination of rosuvastatin calcium in tablets. Pharmazie. 2007;62(6):411\u20133.","journal-title":"Pharmazie"},{"issue":"4","key":"1470_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.14227\/DT300423PGC19","volume":"30","author":"AM Alam","year":"2023","unstructured":"Alam AM, Alhazmi HA, Najmi A, Zoghebi K, Sultan MH, et al. Comparison of Rosuvastatin calcium tablets marketed in Saudi Arabia under Biowaiver conditions in vitro quality control dissolution study. Dissolution Technol. 2023;30(4):19\u201327.","journal-title":"Dissolution Technol"},{"issue":"9","key":"1470_CR19","first-page":"1590","volume":"6","author":"S Navale","year":"2023","unstructured":"Navale S, Pingale M, Bhosale S, Patil P, Ghongade A. Development and validation of UV spectrophotometeric technique for estimation of rosuvastain drug in bulk and pharmaceutical dosage form. J Re Attach Ther Dev Divers. 2023;6(9):1590\u20135.","journal-title":"J Re Attach Ther Dev Divers"},{"issue":"2","key":"1470_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3329\/dujps.v20i2.57170","volume":"20","author":"KYK Sikdar","year":"2021","unstructured":"Sikdar KYK, Nazir MS, Alam MM, Sarkar MR, Rahman SAR. Evaluation of in vitro dissolution profile and physicochemical characterization of polymer based formulations of sparingly soluble rosuvastatin. Dhaka Univ J Pharm Sci. 2021;20(2):199\u2013211.","journal-title":"Dhaka Univ J Pharm Sci"},{"issue":"9","key":"1470_CR21","doi-asserted-by":"publisher","first-page":"e998","DOI":"10.1016\/S2214-109X(18)30275-4","volume":"6","author":"JJ Noubiap","year":"2018","unstructured":"Noubiap JJ, Bigna JJ, Nansseu JR, Nyaga UF, Balti EV, Echouffo-Tcheugui JB, et al. Prevalence of dyslipidaemia among adults in Africa: a systematic review and meta-analysis. Lancet Glob Heal. 2018;6(9):e998-1007.","journal-title":"Lancet Glob Heal"},{"issue":"1","key":"1470_CR22","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/s12872-023-03399-1","volume":"23","author":"N Ali","year":"2023","unstructured":"Ali N, Kathak RR, Fariha KA, Taher A, Islam F. Prevalence of dyslipidemia and its associated factors among university academic staff and students in Bangladesh. BMC Cardiovasc Disord. 2023;23(1):366.","journal-title":"BMC Cardiovasc Disord"},{"issue":"6","key":"1470_CR23","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jsps.2023.04.002","volume":"31","author":"A Matyori","year":"2023","unstructured":"Matyori A, Brown CP, Ali A, Sherbeny F. Statins utilization trends and expenditures in the US before and after the implementation of the 2013 ACC\/AHA guidelines. Saudi Pharm J. 2023;31(6):795\u2013800.","journal-title":"Saudi Pharm J"},{"issue":"3","key":"1470_CR24","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2217\/cer.15.65","volume":"5","author":"OO Akunne","year":"2016","unstructured":"Akunne OO, Godman B, Adedapo AD, Truter I, Fadare J. Statin prescribing among hypertensive patients in southwest Nigeria: findings and implications for the future. J Comp Eff Res. 2016;5(3):281\u20138.","journal-title":"J Comp Eff Res"},{"issue":"1","key":"1470_CR25","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/s13104-019-4423-9","volume":"12","author":"GT Demoz","year":"2019","unstructured":"Demoz GT, Wahdey S, Kasahun GG, Hagazy K, Kinfe DG, Tasew H, et al. Prescribing pattern of statins for primary prevention of cardiovascular diseases in patients with type 2 diabetes: insights from Ethiopia. BMC Res Notes. 2019;12(1):386.","journal-title":"BMC Res Notes"},{"issue":"1","key":"1470_CR26","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12872-020-01482-5","volume":"20","author":"Y Liu","year":"2020","unstructured":"Liu Y, Lv X, Xie N, Fang Z, Ren W, Gong Y, et al. Time trends analysis of statin prescription prevalence, therapy initiation, dose intensity, and utilization from the hospital information system of Jinshan Hospital, Shanghai (2012\u20132018). BMC Cardiovasc Disord. 2020;20(1):201.","journal-title":"BMC Cardiovasc Disord"},{"key":"1470_CR27","unstructured":"Data Bridge. HealthCare. 2023. p. 1\u2013350 Global Statin Market \u2013 Industry Trends and Forecast to 2030. https:\/\/www.databridgemarketresearch.com\/reports\/global-statin-market"},{"key":"1470_CR28","unstructured":"Chia LI. All Crestor recalled after more counterfeits found. Taipei Times. 2017"},{"key":"1470_CR29","unstructured":"Taylor P. Securing Industry. 2017 Taiwan FDA seeks Crestor recall after counterfeit finds. https:\/\/www.securingindustry.com\/pharmaceuticals\/taiwan-fda-seeks-crestor-recall-after-counterfeitfind\/%0As40\/a3433\/#.XXHZ2CgzbIU. Accessed 13 Jan 2024"},{"key":"1470_CR30","unstructured":"The News Himachal. The News Himachal. 2022. Drugs Control Administration seizes counterfeit medicines in Baddi. https:\/\/thenewshimachal.com\/2022\/11\/drugs-control-administration-seizes-counterfeit-medicines-in-baddi\/. Accessed 5 Jan 2024"},{"key":"1470_CR31","unstructured":"Loftus P. Wall Street Journal. 2012. Ranbaxy Halts Production of Generic Lipitor. https:\/\/www.wsj.com\/articles\/SB10001424127887323751104578149383396925280. Accessed 20 Jan 2024"},{"key":"1470_CR32","unstructured":"US Department of Justice. Press Release. 2013. Generic Drug Manufacturer Ranbaxy Pleads Guilty and Agrees to Pay $500 Million to Resolve False Claims Allegations, cGMP Violations and False Statements to the FDA. Available from: https:\/\/www.justice.gov\/opa\/pr\/generic-drug-manufacturer-ranbaxy-pleads-guilty-and-agrees-pay-500-million-resolve-false. Accessed 18 Jan 2024"},{"key":"1470_CR33","unstructured":"ICH. International conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. Validation of analytical procedures: text and methodology Q2(R1). 2005."},{"key":"1470_CR34","first-page":"64","volume":"20","author":"JW Moore","year":"1996","unstructured":"Moore JW, Flanner HH. Mathematical comparison of curves with an emphasis on in vitro dissolution profiles. Pharm Technol. 1996;20:64\u201374.","journal-title":"Pharm Technol"},{"issue":"39","key":"1470_CR35","doi-asserted-by":"publisher","first-page":"46","DOI":"10.9734\/jpri\/2021\/v33i39A32140","volume":"33","author":"ST Monisha","year":"2021","unstructured":"Monisha ST, Ela KN, Islam R, Ether SA, Rahman FI. Quality attributes comparison of selected brands of rosuvastatin calcium tablets marketed in the US and Bangladesh. J Pharm Res Int. 2021;33(39):46\u201355.","journal-title":"J Pharm Res Int"},{"issue":"8","key":"1470_CR36","first-page":"114","volume":"9","author":"S Alam","year":"2021","unstructured":"Alam S, Dilshad H, Khan B, Farooq N, Zehra A. Post marketing in-vitro relative analysis of diverse brands of rosuvastatin calcium accessible in urban Karachi (Pakistan). World J Pharm Sci. 2021;9(8):114\u20139.","journal-title":"World J Pharm Sci"},{"issue":"15","key":"1470_CR37","first-page":"72","volume":"6","author":"F Hasin","year":"2017","unstructured":"Hasin F, Al MMAR, Alam ME, Saha CK, Rahman MdH, Akter S. Cost Effective formulation development of rosuvastatin in compared to innovator brand & evaluation of interchangeability via in-vitro bio-equivalence study. World J Pharm Res. 2017;6(15):72\u201386.","journal-title":"World J Pharm Res"},{"issue":"3","key":"1470_CR38","first-page":"1985","volume":"3","author":"S Naveed","year":"2014","unstructured":"Naveed S, Qamar F. Simple UV spectrophotometric assay of rosuvastatin formulations. Glob J Pharm Res. 2014;3(3):1985\u201390.","journal-title":"Glob J Pharm Res"},{"key":"1470_CR39","volume-title":"Proposal to waive in vivo bioequivalence requirements for the WHO model list of essential medicines immediate release, solid oral dosage forms","author":"World Health Organization (WHO)","year":"2006","unstructured":"World Health Organization (WHO). Proposal to waive in vivo bioequivalence requirements for the WHO model list of essential medicines immediate release, solid oral dosage forms. Geneva: World Health Organization; 2006."}],"container-title":["BMC Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-025-01470-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13065-025-01470-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-025-01470-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T16:06:46Z","timestamp":1745683606000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcchem.biomedcentral.com\/articles\/10.1186\/s13065-025-01470-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1470"],"URL":"https:\/\/doi.org\/10.1186\/s13065-025-01470-w","relation":{},"ISSN":["2661-801X"],"issn-type":[{"value":"2661-801X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"112"}}